CPCL3

CPCL3 is a stable human cartilage-derived progenitor cell line, generated by stabilizing primary cartilage-derived progenitor cells using retroviral SV40. It is being investigated as a cell-based therapy for stimulating meniscus tear healing and providing chondroprotection, particularly in the context of post-traumatic osteoarthritis (OA). The cell line maintains the characteristic cell surface marker phenotype of primary cells (CD54+, CD90+, CD105+, CD166+) and exhibits improved proliferative capacity suitable for extensive expansion. In animal models, intra-articular injection of CPCL3 has been shown to stimulate meniscus tear reintegration and reduce articular cartilage degeneration associated with post-traumatic OA. Its therapeutic effects are linked to its gene expression profile, including higher basal SOX9 expression and lower expression of catabolic enzymes like MMP2, MMP13, and ADAMTS4, compared to bone marrow-derived stromal cells.

Other names

human cartilage-derived progenitor cell line 3stable human cartilage-derived progenitor cell line